MedTrace Logo

X-82 to Treat Age-related Macular Degeneration

NCT02348359 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2022-02-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.

Conditions

  • Age-Related Macular Degeneration (AMD)
  • Macular Degeneration
  • Exudative Age-related Macular Degeneration
  • AMD
  • Macular Degeneration, Age-related, 10
  • Eye Diseases
  • Retinal Degeneration
  • Retinal Diseases

Interventions

DRUG

X-82

DRUG

Anti-VEGF

DRUG

Placebo

Sponsors & Collaborators

  • SynteractHCR

    collaborator INDUSTRY

  • International Drug Development Institute

    collaborator OTHER

  • Tyrogenex

    lead INDUSTRY

Principal Investigators

  • Daniel E Salazar, PhD · Study PI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-16
Primary Completion
2017-12-12
Completion
2018-01-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02348359 on ClinicalTrials.gov